Take the opportunity and register now for the second MedPharmPlast Europe workshop on 3 December 2014 in Brussels.
Expert speakers from the whole plastic medical devices and pharmaceutical packaging supply chain will give you a unique insight into the impact of European legislation on the plastic medical devices and pharmaceutical packaging supply chain. We are delighted to welcome Axel Singhofen, Advisor on Health and Environment Policy for The Greens/EFA in the European Parliament, Linda-Jean Cockcroft from Arkema, Ruth Foster from Terumo BCT and Leonardo Poletti from Polynt as well as Jasmin Bird from the European Information Centre on Bisphenol A and Jenny Gough from EUCOMED. The focus of their presentations will be on:
the latest developments in the European legislation including the much discussed Amendment 355
new insights into substances like DEHP or Bisphenol Athe consequences of the Unique Device Identification for the supply chain
Next to the presentations, there are also panel discussions and network sessions on the agenda.
REGISTER NOW FOR THE MEDPHARMPLAST EUROPE WORKSHOP:
When: Wednesday, 3 December 2014, 11:00 – 16:15
Where: EuPC building, Avenue de Cortenbergh 71, 1000 Brussels
Registration:
The MedPharmPlast workshop is open to everyone involved or interested in the medical devices and pharmaceutical packaging supply chain. If you would like to register for the event or receive more detailed information on it, please contact Erik Hendriks via erik.hendriks@medpharmplasteurope.org or have a look at the attached programme and flyer.
About MedPharmPlast Europe
MedPharmPlast Europe is a sector group of EuPC created in 2014 by and for companies involved in the whole supply chain of plastic medical devices and pharmaceutical packaging in Europe. It assists companies in these industry sectors by keeping them informed about the latest developments in European regulations and their impact on the medical device and pharmaceutical packaging plastics value chain. MedPharmPlast Europe also represents the interests of the industry to the European legislators and tries to arrive at regulations that are both workable and protect the patient.
Comments